Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2024-07-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于2023年限制性股票激励计划第一个归属期归属结果公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the results of the first vesting period of a 2023 restricted stock incentive plan by 圣湘生物科技股份有限公司. It details the number of shares vested, the decision-making process, stock source, restrictions on transfer, and verification by an accounting firm. The document is a formal announcement of the stock incentive plan's vesting results rather than a full report or financial statement. It does not contain comprehensive financial data or detailed management discussion but focuses on the stock incentive plan's implementation and related disclosures. Therefore, it fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement about stock incentive plan vesting results and related compliance information.
2024-07-26 Chinese
圣湘生物科技股份有限公司关于实际控制人兼董事长提议中期分红、注销部分已回购股份暨落实公司2024年度“提质增效重回报”行动方案的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the company regarding a proposal by the actual controller and chairman for an interim dividend distribution, cancellation of repurchased shares, and implementation of a 2024 action plan to improve returns. It includes details about the proposed dividend per share, share cancellation to reduce registered capital, and the need for shareholder approval. The document is relatively short (1097 characters) and serves as a formal announcement of these proposals and upcoming shareholder meeting agenda items. It does not contain actual financial statements or detailed financial data, nor is it a full report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a regulatory announcement about corporate actions and proposals requiring shareholder approval, but not a full report or earnings release.
2024-07-17 Chinese
圣湘生物科技股份有限公司监事会关于2023年限制性股票激励计划第一个归属期归属名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from the Supervisory Board regarding the first vesting period of a 2023 restricted stock incentive plan. It references compliance with company law, securities law, stock exchange listing rules, and internal company regulations. The content focuses on the legality and qualification of incentive recipients rather than financial results, management changes, or shareholder voting. It is not a full report, earnings release, or management discussion. It is also not a notice of voting results or a proxy solicitation. The document is a regulatory compliance statement related to stock incentive plans, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories.
2024-07-08 Chinese
圣湘生物科技股份有限公司章程
Governance Information Classification · 100% confidence The document is a detailed company charter (章程) for 圣湘生物科技股份有限公司, approved at the 2023 Annual General Meeting. It includes comprehensive governance rules, shareholder rights, board structure, share issuance and transfer rules, and other corporate governance matters. It is not a financial report, earnings release, or announcement of voting results. It is a governance document detailing the company's internal rules and structure. Therefore, it fits the category of Governance Information (CGR). The document length (15,000 characters) and content confirm it is the full charter, not a brief announcement or summary.
2024-07-08 Chinese
圣湘生物科技股份有限公司关于变更注册资本、修订《公司章程》并办理工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 圣湘生物科技股份有限公司 regarding changes in registered capital and amendments to the company's articles of association (公司章程). It details the reduction of registered capital due to share cancellation and the corresponding amendments to the articles of association. The document is a formal disclosure of corporate governance changes related to capital structure and company bylaws, not a full financial report or audit. It is not a report publication announcement since it contains substantive information about the changes. This fits the category of Regulatory Filings (RNS) as it is a regulatory announcement about corporate changes that do not fit into more specific categories like Share Issue/Capital Change (SHA) because it involves capital reduction and articles amendment rather than new share issuance or stock splits. Therefore, the best classification is Regulatory Filings (RNS).
2024-07-08 Chinese
圣湘生物科技股份有限公司关于2023年限制性股票激励计划第一个归属期符合归属条件的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 圣湘生物科技股份有限公司 regarding the first vesting period of its 2023 restricted stock incentive plan. It details the number of shares to be vested, the conditions met for vesting, the approval process by the board and supervisory committee, and the legal opinions confirming compliance with relevant laws and regulations. The document is focused on the announcement of the vesting of restricted stock under an equity incentive plan, including specifics about the shares, recipients, and compliance. It is not a full financial report, audit report, or management discussion, but rather a formal announcement of the stock incentive plan's vesting results and conditions met. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about equity incentive plan vesting and related compliance, not a full report or financial statement.
2024-07-08 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.